🔎 Trials Near Me

Início › Câncer Endometrial › Illinois

Ensaios clínicos de Câncer Endometrial em Illinois

38 estudos para Câncer Endometrial estão buscando participantes em locais em Illinois.

Cidades em Illinois

Texto oficial do estudo (Inglês)

Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial

  • Advocate Good Shepherd Hospital, Barrington
  • Illinois CancerCare-Bloomington, Bloomington
  • Illinois CancerCare-Canton, Canton
  • e mais 57
RecrutandoFase 2
Todas as idades · Todos os sexos · Atualizado em 2 de out. de 2026 · NCT05564377

Testing Different Amounts of the Combination of Drugs M1774 and ZEN-3694 for the Treatment of Recurrent Ovarian and Endometrial Cancer

  • University of Chicago Comprehensive Cancer Center, Chicago
RecrutandoFase 1
Idades 18 e acima · Mulheres · Atualizado em 2 de out. de 2026 · NCT05950464

Testing the Addition of an Antiangiogenic Drug (Bevacizumab) to Chemotherapy (Carboplatin and Paclitaxel) Combined With Immunotherapy (Pembrolizumab) for pMMR, TP53 Mutated Endometrial Cancer

  • Northwestern University, Chicago
  • Rush MD Anderson Cancer Center, Chicago
  • University of Chicago Comprehensive Cancer Center, Chicago
  • e mais 26
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 2 de out. de 2026 · NCT07198074

A Study of HER3-DXd in Subjects With Locally Advanced or Metastatic Solid Tumors

  • University of Illinois Cancer Center, Chicago
RecrutandoFase 2
Idades 18 e acima · Todos os sexos · Atualizado em 1 de out. de 2026 · NCT06172478

Leveraging Methylated DNA Markers (MDMs) in the Detection of Endometrial Cancer, Ovarian Cancer, and Cervical Cancer

  • University of Chicago, Chicago
RecrutandoEstudo observacional
Idades 18 e acima · Mulheres · Atualizado em 29 de set. de 2026 · NCT05051722

Testing Nivolumab With or Without Ipilimumab in Deficient Mismatch Repair System (dMMR) Recurrent Endometrial Carcinoma

  • Carle at The Riverfront, Danville
  • Carle Physician Group-Effingham, Effingham
  • Carle Physician Group-Mattoon/Charleston, Mattoon
  • e mais 3
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 28 de set. de 2026 · NCT05112601

DESTINY-PANTUMOUR04

  • Research Site, Decatur
RecrutandoEstudo observacional
Idades de 18 a 130 · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT07124000

Phase 1 Study to Investigate TCRTs KRAS Mutation in Unresectable, Advanced, and/or Metastatic Solid Tumors

  • Research Site, Chicago
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 25 de set. de 2026 · NCT06218914

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

  • Robert H. Lurie Comprehensive Cancer Center of Northwestern University, Chicago
  • University of Chicago Medical Center, Chicago
RecrutandoFase 1/2
Idades 18 e acima · Mulheres · Atualizado em 24 de set. de 2026 · NCT04590326

Adjuvant Therapy in POLE-Mutated and p53-Wildtype/NSMP Early Stage Endometrial Cancer RAINBO BLUE & TAPER

  • Northwestern University, Chicago
  • Northwestern Medicine Orland Park, Orland Park
  • Northwestern Medicine Cancer Center Warrenville, Warrenville
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 24 de set. de 2026 · NCT05640999

Evaluate BL-B01D1 in Patients With Metastatic or Unresectable Non-Small Cell Lung Cancer (NSCLC) and Other Solid Tumors

  • Northwestern University Feinberg School of Medicine, Chicago
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 21 de set. de 2026 · NCT05983432

A Phase 1/2 Trial of TER-2013 in Patients With Solid Tumors Harboring AKT/PI3K/PTEN Pathway Alterations

  • City of Hope, Chicago, Zion
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 17 de set. de 2026 · NCT07109726

A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer

  • OSF Saint Francis Medical Center, Peoria
  • Carle Cancer Institute, Urbana
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 17 de set. de 2026 · NCT06340568

Open Label Study to Evaluate BL-M07D1 in HER2 Expressing Malignant Solid Tumors

  • University of Illinois Cancer Center, Chicago
  • University of Chicago Medicine, Chicago
  • City of Hope - Chicago, Zion
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 10 de set. de 2026 · NCT06293898

Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Investigator's Choice in Participants With Endometrial Cancer

  • Endeavor Health NorthShore, Evanston
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 9 de set. de 2026 · NCT07166094

DESTINY-Endometrial01: A Phase III Study of Trastuzumab Deruxtecan Plus Rilvegostomig or Pembrolizumab as First-Line Treatment of HER2-Expressing (IHC 3+/2+), Mismatch Repair Proficient (pMMR) Endometrial Cancer

  • Research Site, Arlington Heights
  • Research Site, Evanston
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 3 de set. de 2026 · NCT06989112

Phase 1, Safety and Tolerability Study of XmAb541 in Advanced Solid Tumors

  • University of Chicago Medical Center, Chicago
RecrutandoFase 1
Idades 15 e acima · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT06276491

Tegavivint for the Treatment of Recurrent or Refractory Solid Tumors, Including Lymphomas and Desmoid Tumors

  • Lurie Children's Hospital-Chicago, Chicago
RecrutandoFase 1/2
12 Months – 30 Years · Todos os sexos · Atualizado em 25 de ago. de 2026 · NCT04851119

A Phase 2 Study of ACR-368 in Endometrial Adenocarcinoma

  • Northwestern Medicine, Chicago
  • University of Illinois Cancer Center, Chicago
  • University of Chicago Medicine, Chicago
  • e mais 1
RecrutandoFase 2
Idades 18 e acima · Mulheres · Atualizado em 21 de ago. de 2026 · NCT05548296

A Study of Tulmimetostat DZR123 (CPI-0209) in Patients With Advanced Solid Tumors and Lymphomas

  • University of Chicago Medical Center, Chicago
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 19 de ago. de 2026 · NCT04104776

A Study of MUC16-Directed Antibody Drug Conjugate HWK-016 in Participants With Advanced Solid Tumors.

  • St. Francis Medical Center (OSF Healthcare), Peoria
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 18 de ago. de 2026 · NCT07470853

A Study of PHST001 in Advanced Solid Tumors

  • University of Chicago Medical Center, Chicago
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 12 de ago. de 2026 · NCT06840886

Study Evaluating the Safety and Efficacy of HWK-007, a PTK7-directed Antibody Drug Conjugate in Participants With Advanced Solid Tumors

  • St. Francis Medical Center (OSF Healthcare), Peoria
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT07444814

A Study to Evaluate the Efficacy and Safety of Ifinatamab Deruxtecan (I-DXd) in Subjects With Recurrent or Metastatic Solid Tumors (IDeate-PanTumor02)

  • Orchard Healthcare Research Inc, Skokie
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 5 de ago. de 2026 · NCT06330064

A Study of ART0380 for the Treatment of Advanced or Metastatic Solid Tumors

  • Hope and Healing Cancer Services, Hinsdale
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 30 de jul. de 2026 · NCT04657068

Puxitatug Samrotecan (AZD8205) Monotherapy vs Chemotherapy in B7-H4-selected Endometrial Cancer (Bluestar-Endometrial01)

  • Research Site, Chicago
  • Research Site, Peoria
  • Research Site, Urbana
RecrutandoFase 3
Idades 18 e acima · Mulheres · Atualizado em 29 de jul. de 2026 · NCT07044336

Integrated Cancer Repository for Cancer Research

  • Rush-Copley Cancer Care Center, Aurora
  • Rush-Copley Healthcare Center, Yorkville
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 19 a 110 · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT02012699

A Study of Emiltatug Ledadotin (Emi-Le) in Participants With Solid Tumors

  • Northwestern University, Chicago
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 29 de jun. de 2026 · NCT05377996

A Study of LY4175408 in Participants With Advanced Cancer

  • The University of Chicago Medical Center (UCMC), Chicago
RecrutandoFase 1
Idades 18 e acima · Todos os sexos · Atualizado em 23 de jun. de 2026 · NCT07046923

Physical Activity Intervention Among Older Women With Gynecologic Cancers (Fit4Treatment)

  • Northwestern University, Chicago
Recrutando
Idades 60 e acima · Mulheres · Atualizado em 29 de mai. de 2026 · NCT05743517

A Study of PARG Inhibitor ETX-19477 in Patients With Advanced Solid Malignancies

  • University of Chicago Medical Center, Chicago
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 27 de mar. de 2026 · NCT06395519

Alternate Day Fasting After Surgery for Patients Undergoing Chemotherapy

  • Northwestern Memorial Hospital, Chicago
Recrutando
Idades 18 e acima · Mulheres · Atualizado em 24 de mar. de 2026 · NCT05990426

A Phase I/II Study of VLS-1488 in Subjects With Advanced Cancer

  • Kellogg Cancer Center, Evanston
RecrutandoFase 1/2
Idades 18 e acima · Todos os sexos · Atualizado em 4 de nov. de 2025 · NCT05902988

SYNERGY-AI: Artificial Intelligence Based Precision Oncology Clinical Trial Matching and Registry

  • Massive Bio SYNERGY-AI site, Chicago
RecrutandoEstudo observacional
Todas as idades · Todos os sexos · Atualizado em 28 de out. de 2025 · NCT03452774

Specimen and Data Study for Ovarian Cancer Early Detection and Prevention

  • Robert H. Lurie Comprehensive Cancer Center at Northwestern University, Chicago
RecrutandoEstudo observacionalVoluntários saudáveis bem-vindos
Idades de 18 a 80 · Mulheres · Atualizado em 28 de fev. de 2025 · NCT00005095

Study of Navtemadlin as Maintenance Therapy in TP53WT Advanced or Recurrent Endometrial Cancer

  • Dr. Sudarshan K. Sharma, Ltd., Hinsdale
RecrutandoFase 2/3
Idades 18 e acima · Mulheres · Atualizado em 2 de mai. de 2024 · NCT05797831

Fonte: ClinicalTrials.gov, dados obtidos em 5 de out. de 2026. Cada estudo define seus próprios critérios de elegibilidade; a equipe do estudo decide quem pode participar.